In this project the investigators decide to evaluate the efficacy and safety of half dose
mabthera (it means 500 mg infusion two weeks apart) in conventional drug resistant cases of
rheumatoid arthritis. The investigators choose this drug because the use of anti-TNF drugs
limited in the investigators refractory patients as the first line drugs because of its cost.